# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of t...
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $8 price target.
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $5 price target.
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by...
RBC Capital analyst Kennen MacKay maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $4 t...
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...